Blood cancer incidence, mortality and survival for Māori in New Zealand (opens on the publisher’s website)
Cancer Epidemiology · 2024
Clough S, Wheeler M, Stanley J, Signal V, Ruka M, Koea J, Gurney J
- What it found
- Using national Cancer Registry data from 2007 to 2019 (2,653 Māori and 20,458 European blood cancer registrations), the study found Māori were more likely than Europeans to be diagnosed with, and to die from, leukaemia and myeloma, and had similar rates of Hodgkin and non-Hodgkin lymphoma. Māori had poorer cancer-specific survival across nearly all blood cancer types – age-sex-adjusted hazard ratios were 1.77 for leukaemia, 1.71 for non-Hodgkin lymphoma, 1.40 for myeloma and 1.18 for Hodgkin lymphoma, the last with a wide confidence interval reflecting the small number of cases. Within leukaemia, the survival gap was narrowest under 25 and widest in the 25–64 age bands. The authors call for further research to pinpoint where in the pathway the survival gap arises.
- How it was done
- retrospective national registry cohort, 2,653 Māori and 20,458 European blood cancer registrations, NZ Cancer Registry 2007–2019, linked to mortality data to 2018
- Why it matters
- It gives registry-level numbers, not an estimate, for a group of cancers that gets less attention in Māori cancer commentary than the larger solid-tumour cancers.
- What it does not settle
- A registry and mortality-linkage study can show the size of a gap but not explain it. The authors themselves flag the Hodgkin lymphoma estimate as imprecise because of low case numbers. Read from the full published version-of-record PDF (CC BY licence, Otago OUR Archive).
Full textfull text
Read it free: Blood cancer incidence, mortality and survival for Māori in New Zealand (opens on another organisation’s website)DOI 10.1016/j.canep.2024.102656